AbbVie Dividends and Buybacks

Dividend criteria checks 4/6

AbbVie is a dividend paying company with a current yield of 3.82%. Next payment date is on 14th February, 2025 with an ex-dividend date of 15th January, 2025.

Key information

3.8%

Dividend yield

0.4%

Buyback Yield

Total Shareholder Yield4.2%
Future Dividend Yield4.1%
Dividend Growth1.1%
Next dividend pay date14 Feb 25
Ex dividend date15 Jan 25
Dividend per shareUS$6.560
Payout ratio216%

Recent dividend and buyback updates

AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year

Jan 03
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64

Dec 09
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Nov 19
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Recent updates

AbbVie's Stock Is Unfairly Cheap

Jan 09

AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year

Jan 03
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year

Betting Big On AbbVie: A Prescription For Growth And Dividends

Dec 11

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64

Dec 09
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.64

AbbVie: Upgrading To 'Strong Buy' After Pullback

Nov 22

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Nov 19
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

Nov 12
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

AbbVie Stock: Keep Calm And Buy The Dip

Nov 11

AbbVie: 3 Positives From The Earnings Report

Oct 30

AbbVie: Strong Dividends But Humira Disappoints

Oct 22

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Sep 29

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Sep 06
We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Why AbbVie Remains One Of My Favorite Dividend Growers

Aug 27

AbbVie: Growth Is Still A Better Choice

Jul 29

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Jul 17

AbbVie: A Hold Again (Rating Downgrade)

Jul 03

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

Jun 28
Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie: 5 Reasons That Make A Buy Case

Jun 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: ABBV's dividends per share have been stable in the past 10 years.

Growing Dividend: ABBV's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

AbbVie Dividend Yield vs Market
How does ABBV dividend yield compare to the market?
SegmentDividend Yield
Company (ABBV)3.8%
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (ABBV) (up to 3 years)4.1%

Notable Dividend: ABBV's dividend (3.82%) is higher than the bottom 25% of dividend payers in the US market (1.43%).

High Dividend: ABBV's dividend (3.82%) is low compared to the top 25% of dividend payers in the US market (4.49%).


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (215.8%), ABBV's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (74.2%), ABBV's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 22:34
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AbbVie Inc. is covered by 55 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Luisa HectorBerenberg